{"commentary":{"count":78,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":36,"podcast":21,"x_thread":20,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05023980\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"BRUIN-CLL-313","nct_id":"NCT05023980","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bruin-cll-313-nct05023980. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"BRUIN-CLL-313","arms":[{"description":"Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.","label":"Arm A - Pirtobrutinib","type":"EXPERIMENTAL"},{"description":"Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).","label":"Arm B - Bendamustine Plus Rituximab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eli Lilly and Company"],"completion_date":{"date":"2027-10","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":{"count":282,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pirtobrutinib","type":"DRUG"},{"name":"Bendamustine","type":"DRUG"},{"name":"Rituximab","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Loxo Oncology, Inc.","official_title":"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)","timeFrame":"From randomization until documented disease progression or death (up to 40 months)"}],"references":[{"citation":"Eyre TA, Hess LM, Masoudi E, Jen MH, Abhyankar S, Graham-Clarke PL, Bhandari NR, Maguire P, Winfree KB, Tracey M, Taipale KL, Davids MS. Efficacy of Pirtobrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2026 Feb 18;18(4):660. doi: 10.3390/cancers18040660.","pmid":"41749915","type":"DERIVED"},{"citation":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2026 Feb 20;44(6):466-475. doi: 10.1200/JCO-25-02380. Epub 2025 Dec 9.","pmid":"41363773","type":"DERIVED"}],"start_date":{"date":"2021-09-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","url":"https://clinicaltrials.gov/study/NCT05023980"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bruin-cll-313-nct05023980"}